Please ensure Javascript is enabled for purposes of website accessibility

Why Horizon Pharma PLC Earned a Higher Stock Price

By Brian Orelli, PhD - May 9, 2016 at 7:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The spec pharma meets its expectations.

Image source: Horizon Pharma.

What: Horizon Pharma (HZNP 1.35%) jumped nearly 14% today after releasing first-quarter results.

Of course the jump is all relative, as the company dropped Friday in anticipation of the earnings report. The stock traded higher than it closed today as recently as last Tuesday.

So what: The ironic part of the down-then-up stock movement is that Horizon Pharma had already released preliminary revenue guidance, stating that about 19% to 20% of its expected 2016 sales of $1.025 billion to $1.050 billion would come in the first half. Do the math and you get revenue between $195 million and $210 million.

HZNP Price Chart

HZNP Price data by YCharts

First-quarter sales came in at $205 million, pretty close to the midpoint of that range. The 81% year-over-year increase was driven by sales of Krystexxa and Ravicti that it acquired from Crealta Pharmaceuticals and Hyperion Therapeutics respectively as well as Pennsaid, which saw sales more than triple year over year.

Now what: It's all about acceleration for Horizon Pharma. Management expects 57% to 59% of its 2016 net sales to come in the second half of the year. And 2016 adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) are expected to accelerate even faster with 64% to 66% of the $505 million to $520 million coming in the back half of the year.

If Horizon can hit those numbers, investors will be seeing more up than down days.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
$80.84 (1.35%) $1.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.